Hormone therapy after risk-reducing surgery in patients with BRCA1/BRCA2 mutation: evaluation of potential benefits and safety.

Autor:	Silva Filho ALD; Professor Titular do Departamento de Ginecologia e Obstetrícia da UFMG, Belo Horizonte, MG, Brasil., Carvalho GM; Acadêmico da Faculdade de Medicina da UFMG, Belo Horizonte, MG, Brasil., Sena LC; Acadêmico da Faculdade de Medicina da UFMG, Belo Horizonte, MG, Brasil., Gomes LPG; Acadêmico da Faculdade de Medicina da UFMG, Belo Horizonte, MG, Brasil., Valério MFH; Acadêmico da Faculdade de Medicina da UFMG, Belo Horizonte, MG, Brasil., Martins RIL; Médica Residente em Ginecologia e Obstetrícia do Hospital das Clínicas da UFMG, Belo Horizonte, MG, Brasil., Cândido EB; Professor Adjunto do Departamento de Ginecologia e Obstetrícia da Faculdade de Medicina da UFMG, Belo Horizonte, MG, Brasil.
Jazyk:	angličtina
Zdroj:	Revista da Associacao Medica Brasileira (1992) [Rev Assoc Med Bras (1992)] 2020 Aug; Vol. 66 (8), pp. 1134-1138.
DOI:	10.1590/1806-9282.66.8.1134
Abstrakt:	Women with mutations in the BRCA 1 and 2 genes are at increased risk for ovarian and breast cancer and therefore candidates for risk-reducing surgery, including salpingo-oophorectomy and mastectomy. Risk-reducing salpingo-oophorectomy (RRSO) is considered the most effective prophylactic measure for ovarian cancer prevention in this group of patients. This procedure involves loss of ovarian function and induced menopause. Estrogen therapy is the most effective treatment for controlling vasomotor symptoms and improving the quality of life of climacteric women. However, the potential hormonal stimulation of these tumors and the risk of breast cancer are a concern regarding the safety of hormone replacement therapy (HRT) in this population. This article aims to review the current evidence regarding the potential benefits and safety of HRT after RRSO.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu